Last reviewed · How we verify
PF-07321332 Dose 2 (pf-07321332-dose-2)
PF-07321332 Dose 2, marketed by Pfizer Inc., holds a significant position in its therapeutic area, though specific revenue figures are not provided. The drug's key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the upcoming patent expiry, which could erode market exclusivity and revenue.
At a glance
| Generic name | pf-07321332-dose-2 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS (PHASE1)
- Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07321332 Dose 2 CI brief — competitive landscape report
- PF-07321332 Dose 2 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI